We believe that patients with poor performance status and activating EGFR mutation tumours should receive erlotinib or gefitinib, in line with the established evidence in patients with good performance status, and supported by the finding that the small number of these patients in TOPICAL all developed rash.7, 8, 14. This evidence concerns the gene EGFR and exanthem.